Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., filed a Form 4 on November 10, 2026, disclosing an acquisition of 1,596 shares of common stock on November 6, 2026, at a price of $0.845 per share.

Key Highlights

  • Reporting person: Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc. (NASDAQ:IMNN)
  • Transaction: Acquisition (Code A) of 1,596 shares of common stock on November 6, 2026, at $0.845 per share
  • Post-transaction ownership: Faller directly holds 76,356 shares of common stock following the reported transaction
  • Nature of grant: According to the filing remarks, the shares were part of a stock grant, with 1.092 shares granted in lieu of cash for a portion of base salary
  • Filing signed: Jeffrey W. Church, Attorney in Fact for Douglas Faller, signed the filing on November 10, 2026

Faller's November 2026 Stock Acquisition at Imunon

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 10, 2026, Douglas Vincent Faller, identified as Chief Medical Officer of Imunon, Inc. (NASDAQ:IMNN), reported an acquisition of 1,596 shares of Imunon common stock. The transaction date was November 6, 2026, with shares acquired at a price of $0.845 each. The filing records the transaction under Code A, indicating an acquisition of securities.

The filing's remarks section notes that the transaction relates to a "Stock Grant (26,741 shares)" and that 1.092 shares were "granted in lieu of cash for portion of base salary." Following the reported transaction, the filing states that Faller directly and beneficially owns 76,356 shares of Imunon common stock. No derivative securities were reported in Table II of the filing.

The Form 4 was filed by one reporting person and was signed by Jeffrey W. Church as Attorney in Fact for Douglas Faller. The filing does not indicate that any transaction was made pursuant to a Rule 10b5-1(c) plan, as the relevant checkbox was not marked.

What Was Disclosed

Imunon's Chief Medical Officer, Douglas Vincent Faller, disclosed an acquisition of 1,596 shares of common stock on November 6, 2026, at $0.845 per share, bringing his direct beneficial ownership to 76,356 shares, with the shares described as a stock grant partially in lieu of base salary.